Previous studies have focused on the pharmacological effects and clinical potential of FGF21 in cardiovascular diseases and metabolic diseases such as diabetes mellitus, obesity, and insulin resistance [8, 32–35]. Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.